Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

After hours: March 24 at 7:44:11 PM EDT Loading Chart for VRTX ...

Sensex up 900 pts, Nifty over 23,600; surging bank shares, other factors behind rally Meesho picks Morgan Stanley, Kotak and Citi as bankers for $1 billion IPO at valuation of $10 billion Freedom ...

Disclaimer: There maybe definitely a variance in rates and prices. GoodReturns.in has made every effort to ensure accuracy of information provided; however, Greynium Information Technologies Pvt ...

Competition page helps you compare EMA Partners India Ltd. with its sector peers on key parameters.